Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.ACST · Entity 7266 | Director | July 14, 2023 | July 18, 2023 |
| PaxMedica, Inc.PXMD · Entity 93047 | 10% owner | November 27, 2023 | November 29, 2023 |
| Timber Pharmaceuticals, Inc.TMBR · Entity 110330 | Director · Executive Chairman | May 18, 2020 | May 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date July 14, 2023 · Filed July 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2033-07-14 | Direct | 12,500 |
Reported balance
After 2023-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-14 · Grant · Acquired 12,500 · Balance 12,500 F1: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months.
PaxMedica, Inc.
Report date November 27, 2023 · Filed November 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,650 |
Reported balance
After 2023-11-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-11-27 · Sale · Disposed 185 · Balance 25,650 F1: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs. F2: The sale price represents the weighted average sale price of the shares sold ranging from $0.97 to $1.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Reflects a 1-for-17 reverse stock split effective October 30, 2023. |
| Common StockSEC Table I · non-derivative | IndirectTardiMed Sciences, LLC | 431,574 |
Reported balance
Holding disclosure · report date 2023-11-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 431,574 F4: Reflects a 1-for-17 reverse stock split effective October 30, 2023. F3: The reporting person is the managing partner of TardiMed Sciences, LLC and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs.
F2: The sale price represents the weighted average sale price of the shares sold ranging from $0.97 to $1.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3: The reporting person is the managing partner of TardiMed Sciences, LLC and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F4: Reflects a 1-for-17 reverse stock split effective October 30, 2023.
Timber Pharmaceuticals, Inc.
Report date May 18, 2020 · Filed May 20, 2020
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 27, 2023 Filed Nov 29, 2023 16:08 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 185 | $1.03 | $189.88 |
DisclosureSEC source: 0001062993-23-021595 · form4.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,650 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs. F2 · price: The sale price represents the weighted average sale price of the shares sold ranging from $0.97 to $1.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · balance_after: Reflects a 1-for-17 reverse stock split effective October 30, 2023. Read SEC document |
| October 27, 2023 Filed Oct 30, 2023 16:12 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 9,175 | $0.19 | $1,740.50 |
DisclosureSEC source: 0001062993-23-019823 · form4.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,171 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs. F2 · price: The sale price represents the weighted average sale price of the shares sold ranging from $0.186 to $0.191 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4 · balance_after: Does not reflect a 1-for-17 reverse stock split effective October 30, 2023. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 16:08 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 6,540 | $0.48 | $3,168.63 |
DisclosureSEC source: 0001062993-23-017281 · form4.xml · nonDerivative · entry 2 Derby Michael · CIK 0001809613 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 448,346 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs. F3 · price: The sale price represents the weighted average sale price of the shares sold ranging from $0.4844 to $0.5024 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 16:08 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 7,000 | $0.49 | $3,451.70 |
DisclosureSEC source: 0001062993-23-017281 · form4.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,886 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs. F2 · price: The sale price represents the weighted average sale price of the shares sold ranging from $0.4767 to $0.5005 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 16:12 UTC | PaxMedica, Inc. PXMD · Entity 93047 | Tax withholdingCommon Stock | 6,272 | $0.72 | $4,497.02 |
DisclosureSEC source: 0001062993-23-015427 · form4.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,886 F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 16:37 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-015000 · form4.xml · derivative · entry 1 Derby Michael · CIK 0001809613 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Shares · 12,500 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 16:12 UTC | PaxMedica, Inc. PXMD · Entity 93047 | Tax withholdingCommon Stock | 6,272 | $1.61 | $10,097.92 |
DisclosureSEC source: 0001104659-23-052962 · tm2314131-5_4seq1.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,158 F1 · kind: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 19:11 UTC | PaxMedica, Inc. PXMD · Entity 93047 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-045774 · tm2312952-3_4seq1.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,430 F1 · kind: Consists of 150,000 restricted stock units ("RSUs"). The RSUs are subject to time-based vesting with one-third of the RSUs vesting on February 1, 2024, followed by 8.3325% of the remaining RSUs vesting on a quarterly basis thereafter, subject to the reporting person's continuous employment with the Company as of such vesting dates. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 21:47 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 2,143 | $1.43 | $3,064.49 |
DisclosureSEC source: 0001104659-23-030758 · tm239104d3_4.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,430 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.54 to $1.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 07, 2023 Filed Mar 7, 2023 19:17 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 15,134 | $1.55 | $23,457.70 |
DisclosureSEC source: 0001104659-23-029720 · tm238845-1_4seq1.xml · nonDerivative · entry 2 Derby Michael · CIK 0001809613 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,573 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.67 to $1.45 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 06, 2023 Filed Mar 7, 2023 19:17 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 13,828 | $1.72 | $23,784.16 |
DisclosureSEC source: 0001104659-23-029720 · tm238845-1_4seq1.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,707 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.90 to $1.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 20:10 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 18,968 | $1.90 | $36,039.20 |
DisclosureSEC source: 0001104659-23-028617 · tm238562d1_4.xml · nonDerivative · entry 2 Derby Michael · CIK 0001809613 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,535 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.98 to $1.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 20:10 UTC | PaxMedica, Inc. PXMD · Entity 93047 | SaleCommon Stock | 10,497 | $1.94 | $20,364.18 |
DisclosureSEC source: 0001104659-23-028617 · tm238562d1_4.xml · nonDerivative · entry 1 Derby Michael · CIK 0001809613 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,503 F1 · kind: The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $2.09 to $1.87 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 16:18 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001171843-22-006332 · ownership.xml · derivative · entry 1 Derby Michael · CIK 0001809613 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Class A Common Shares · 85,000 shares Expires 2032-09-28 F1 · derivative.exercise_price: Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 16:06 UTC | PaxMedica, Inc. PXMD · Entity 93047 | PurchaseCommon Stock | 95,000 | $5.25 | $498,750.00 |
DisclosureSEC source: 0001104659-22-097017 · tm2224962-1_4seq1.xml · nonDerivative · entry 2 Derby Michael · CIK 0001809613 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · TardiMed Sciences, LLC Disclosed balance after: 7,336,745 F2 · kind: These shares were purchased from the underwriters by TardiMed Sciences, LLC ("TardiMed") in the issuer's initial public offering, which closed on August 30, 2022. See footnote 3 for the reporting person's relationship to TardiMed. F3 · ownership.nature: The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.